Czy u chorych na HER2-dodatniego raka piersi z przerzutem do mózgu rozpoznanym w trakcie leczenia trastuzumabem należy zmienić lek? Głos na TAK | Zendy

AI Assistant Blog Pricing

Open Access

Czy u chorych na HER2-dodatniego raka piersi z przerzutem do mózgu rozpoznanym w trakcie leczenia trastuzumabem należy zmienić lek? Głos na TAK

Author(s) -

Renata Duchnowska

Publication year - 2015

Publication title -

nowotwory journal of oncology

Language(s) - Polish

Resource type - Journals

SCImago Journal Rank - 0.115

H-Index - 8

eISSN - 2300-2115

pISSN - 0029-540X

DOI - 10.5603/njo.2015.0028

Subject(s) - medicine , gastroenterology

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Download on the

Discover

Explore

Copyright Knowledge E © 2026. All Rights Reserved.